PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

New prescriptions of Allergan’s Esyma on hold

Doctors are not to prescribe Allergan’s Esmya for uterine fibroids in the UK while European regulators carry out a safety review of the drug.
The European Medicines Agency started a review of Esmya (ulipristal acetate) for uterine fibroids in December following reports of four cases of serious liver injury after its use, leading to liver transplants in three of the cases.
Temporary safety measures have now been introduced advising that no new treatment courses with the drug should be initiated while the review is ongoing, and that those already taking it have blood tests to monitor their liver function at least once a month.
If the test is abnormal, showing liver enzyme levels more than two times the upper limit of normal, the healthcare professional should stop treatment and closely monitor the patient, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has stressed.
Esmya was first approved in the EU in 2012 for the treatment of moderate to severe symptoms of uterine fibroids – non-cancerous (benign) tumours of the womb – in women who have not reached the menopause.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026